Diagnostic signature uses artificial intelligence to detect long-term concussion

Lawyers representing both sides in concussion lawsuits against sports leagues may eventually have a new tool at their disposal: a diagnostic signature that uses artificial intelligence to detect brain trauma years after it has occurred.

While the short-term effects of head trauma can be devastating, the long-term effects can be equally hard for patients. The symptoms may linger years after the concussion happened. The problem is it is often hard to say whether their symptoms are being caused by a concussion or other factors like another neurological condition or the normal aging process.

The only way to prove the presence of brain damage caused by concussion years after it occurred was through post-mortem examination. A means of diagnosing concussion in living patients, however, remained elusive.

A research team from Université de Montreal, The Montreal Neurological Institute and Hospital (The Neuro), and the Ludmer Center for NeuroInformatics recruited former university athletes between the ages of 51 and 75 who played contact sports such as ice hockey and American football. From that group, the researchers formed a cohort of 15 athletes who reported being concussed in their athletic careers, and a control group of 15 athletes who had not been concussed.

The researchers performed a battery of tests on both groups, including neuropsychological testing, genotyping, structural neuroimaging, magnetic resonance spectroscopy, and diffusion weighted imaging. They then pooled the data and fed it to computers that use artificial intelligence software to "learn" the differences between the brain of a healthy athlete versus the brain of a previously concussed athlete. They found that white matter connections between several brain regions of concussed individuals showed abnormal connectivity that might reflect both degeneration and the brain's method of compensating for damage. Using the data, the computers were able to detect concussion with up to 90-per-cent accuracy.

The study's results were published in the European Journal of Neuroscience on May 16, 2017. Their work, once more thoroughly tested and refined, could have implications for current and future concussion lawsuits. The National Football League, for example, faced a decade-long lawsuit by former players who claimed it did not do enough to protect them from concussion. The lawsuit was complicated by the fact there was no objective way to determine if the neurological symptoms they experienced were caused by the concussions they received as players. The National Hockey League is currently facing a similar lawsuit by former players.

Dr. Sebastien Tremblay, the paper's first author, says they need to validate the signature on a larger sample size, using various magnetic resonance imaging (MRI) scanners, before it becomes an effective means to diagnose concussion. When perfected, the signature could also aid treatment of concussion by providing doctors with an accurate picture of what is causing their patients' symptoms.

The need for such tools is greater than ever. According to the federal government, reported concussions have increased 40 per cent between 2004 and 2014 among young football, soccer and hockey players.

"With 1.6 to 3.8 million concussions per year in the US alone, the prevalence of this injury is alarming," says Tremblay, a postdoctoral researcher at The Neuro. "It is unacceptable that no objective tools or techniques yet exist to diagnose them, not to mention the sheer lack of scientifically valid treatment options. With our work, we hope to provide help to the vast population of former athletes who experience neurological issues after retiring from contact sport."

"Future studies, including systematic comparisons with patient groups presenting with other age-related neurological conditions, together with identifying new biomarkers of concussion, would help refine the developed, computer-assisted model of the remote effects of concussion on the aging brain," says Dr. Louis de Beaumont, a researcher at Université de Montreal and the paper's senior author.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New AI-driven platform enhances lung cancer tissue analysis